Community-acquired pneumonia (CAP) is a systemic disease and continues to be the leading cause of infectious mortality ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Respiratory tract diseases are illnesses that affect components of the respiratory system, including the nasal passages, the bronchi and the lungs. They range from acute infections, such as ...

The first U.S. H5N9 outbreak has raised concerns as scientists warn of evolving bird flu risks—here's what you need to know about the symptoms.

Researchers reveal how targeting HIF2 could transform the treatment of idiopathic pulmonary fibrosis (IPF), offering hope for ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...